Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
September, 2026
September 2026
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Abeer Alanazi: Asundexian Reduces Stroke and Mortality Without Increased Bleeding
photo: ajmc.com
Feb 7, 2026, 15:24

Abeer Alanazi: Asundexian Reduces Stroke and Mortality Without Increased Bleeding

Abeer Alanazi, American Board Certified Pharmacotherapy Specialist and member at European Stroke Organisation (ESO), shared a post on LinkedIn.

“OCEANIC-STROKE

  • Patients with non-cardioembolic ischemic stroke or TIA
  • Concomitant dual antiplatelet therapy (DAPT)
  • Asundexian initiated within 72 hours of symptom onset
  • 6,162 patients received asundexian; 6,165 received placebo
  • Treatment duration: 3–31 months
  • 30% of patients had NIHSS >4

Efficacy

  •  Significant reduction in acute ischemic stroke (AIS)
  • Significant reduction in cardiovascular mortality
  •  Significant reduction in all-cause mortality

Treatment effects were consistent across the overall population and all prespecified subgroups throughout the treatment period.

Safety

  • No increase in major bleeding
  • No increase in non-major bleeding
  •  No increase in symptomatic intracranial hemorrhage (sICH)
  • No increase in hemorrhagic stroke
  •  No increase in fatal bleeding”

Abeer Alanazi: Asundexian Reduces Stroke and Mortality Without Increased Bleeding

Stay updated with Hemostasis Today.

 

Health Hematology Hemostasis Hemostasis News Hemostasis Today ISC26 Medicine thrombosis
NewsFeed